Haanen JBAG - Search Results

1

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: haanen jbag. Clin Cancer Res. 2020 May 1;26(9):2268-2274. doi: 10.1158/1078-0432.CCR-19-3322. Epub 2020 Jan 27. Clin Cancer Res. 2020. PMID: 31988197

2

On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.

van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, Van Tinteren H, Schumacher T, Haanen J. van Oijen M, et al. Clin Cancer Res. 2004 Jul 15;10(14):4754-60. doi: 10.1158/1078-0432.CCR-04-0260. Clin Cancer Res. 2004. PMID: 15269149

3

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Haanen JB, et al. Cancer Immunol Immunother. 2006 Apr;55(4):451-8. doi: 10.1007/s00262-005-0018-5. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034562 Free PMC article. Clinical Trial.

4

Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.

Vuylsteke RJ, Molenkamp BG, van Leeuwen PA, Meijer S, Wijnands PG, Haanen JB, Scheper RJ, de Gruijl TD. Vuylsteke RJ, et al. Clin Cancer Res. 2006 May 1;12(9):2826-33. doi: 10.1158/1078-0432.CCR-05-2431. Clin Cancer Res. 2006. PMID: 16675577 Clinical Trial.

5

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. de Mulder PH, et al. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Ned Tijdschr Geneeskd. 2008. PMID: 18380383 Review. Dutch.

6

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E. van der Veldt AA, et al. Clin Cancer Res. 2008 Apr 15;14(8):2431-6. doi: 10.1158/1078-0432.CCR-07-4089. Clin Cancer Res. 2008. PMID: 18413834

7

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. van der Veldt AA, et al. Br J Cancer. 2008 Jul 22;99(2):259-65. doi: 10.1038/sj.bjc.6604456. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594533 Free PMC article. Clinical Trial.

8

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Molenkamp BG, et al. Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711. Clin Cancer Res. 2008. PMID: 18628468 Clinical Trial.

9

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.

van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101

10

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Bex A, et al. World J Urol. 2009 Aug;27(4):533-9. doi: 10.1007/s00345-008-0368-7. Epub 2009 Jan 15. World J Urol. 2009. PMID: 19145434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

450 results

Search Page

Filters